Melatonin alleviates bleomycin-induced pulmonary fibrosis in mice

Journal of Biological Regulators and Homeostatic Agents

Volumn 29, Issue 2, 2015, Pages 327-334

  Karimfar, M H ^a,b   Rostami, S ^a   Haghani, K ^a   Bakhtiyari, S ^a   Noori Zadeh, A ^a  

^a ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bleomycin; Cyclooxygenase 2; Melatonin; Pulmonary fibrosis

Indexed keywords

BLEOMYCIN; COLLAGEN; CYCLOOXYGENASE 2; MELATONIN; ANTIOXIDANT; CYCLOOXYGENASE 2 INHIBITOR; PTGS2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; IRAN; MALE; MORTALITY; MORTALITY RATE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WEIGHT REDUCTION; ANIMAL; BIOSYNTHESIS; BODY WEIGHT; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; LUNG; LUNG ALVEOLUS; PATHOLOGY; PRECLINICAL STUDY; PULMONARY EDEMA; PULMONARY FIBROSIS;

ANIMALS; ANTIOXIDANTS; BLEOMYCIN; BODY WEIGHT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION, PRECLINICAL; ENZYME INDUCTION; LUNG; MALE; MELATONIN; MICE; MICE, INBRED C57BL; PULMONARY ALVEOLI; PULMONARY EDEMA; PULMONARY FIBROSIS;

EID: 84970926735     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011; 163:141-72.
2. Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy 2010; 65:537-53.
3. Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV, Waldron JA, Centers C. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: A multicenter case- control study. Am J Epidemiol 2000; 152:307-15.
4. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008; 3:8.
5. Kinnula VL, Fattman CL, Tan RJ, Ouiy TD. Oxidative stress in pulmonary fibrosis: A possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005; 172:417-22.
6. Fitz Gerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Disco 2003; 2:879-90.
7. Chenevard R, Htirlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107:405-9.
8. Wilborn J, Crofford L, Burdick M, Kunkel S, Strieter R, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95:1861.
9. Huang SK, Peters-Golden M. Eicosanoid lipid mediators in fibrotic lung diseasesready for prime time? CHEST J 2008; 133:1442-50.
10. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future. Am J Respir Crit Care Med 1999; 160:1771-77.
11. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med 2011; 17:355-61.
12. El-Demerdash E. Anti-inflammatory and antifibrotic effects of methyl palmitate. Toxicol appl pharmacol 2011;254:238-44.
13. Kalayarasan S, Sriram N, Sudhandiran G. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: Critical role of iNOS, NF-kB, TNF-A and IL-lp. Life Sci 2008; 82:1142-53.
14. Thrall R, McCormick J, Jack R, McReynolds R, Ward P. Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol 1979; 95:117.
15. Ambriz-Tututi M, Rocha-Gonzalez HI, Cruz SL, Granados-Soto V. Melatonin: A hormone that modulates pain. Life Sci 2009, 84(15):489-98.
16. Cutando A, Gomez-Moreno G, Arana C, Acuna- Castroviejo D, Reiter RJ. Melatonin: potential functions in the oral cavity. J Periodontal 2007; 78:1094-102.
17. Mauriz JL, Collado PS, Veneroso C, Reiter RJ, Gonzalez-Gallego J. A review of the molecular aspects of melatonin's anti-inflammatory actions: Recent insights and new perspectives. J Pineal Res 2013, 54:1-14.
18. Kannen V, Marini T, Zanette DL, Frajacomo FT, Silva GE, Silva Jr WA, Garcia SB. The melatonin action on stromal stem cells within pericryptal area in colon cancer model under constant light. Biochem Biophys Res Commun 2011; 405:593-98.
19. Dong W-G, Mei Q, Yu J-P, Xu J-M, Xiang L, Xu Y. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 2003;9:1307-11.
20. Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L, Liu L, Xie F, Kang T, Huang W. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012; 53:77-90.
21. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: An established antioxidant worthy of use in clinical trials. Mol Med 2009; 15:43-50.
22. Yacoubi L, Rabaoui L, Hamdaoui MH, Fattouch S, Serairi R, Kourda N, Khamsa SB. Anti-oxidative and anti-inflammatory effects of Trigonella foenum- graecum Linnaeus, 1753 (Fenugreek) seed extract in experimental pulmonary fibrosis. J Med Plants Res 2011; 5:4315-25.
23. Genovese T, Paola RD, Mazzon E, Muia C, Caputi AP, Cuzzocrea S. Melatonin limits lung injury in bleomycin treated mice. J Pineal Res 2005; 39:105-12.
24. Oga T, Matsuoka T, Yao C, Nonomura K, Kitaoka S, Sakata D, Kita Y, Tanizawa K, Taguchi Y, Chin K. Prostaglandin F2a receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-p. Nat Med 2009; 15:1426-30.
25. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002; 165:229-35.